See more : Deoleo, S.A. (SOSCF) Income Statement Analysis – Financial Results
Complete financial analysis of Savara Inc. (SVRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Savara Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Uniti S.A (ALUNT.PA) Income Statement Analysis – Financial Results
- DeNA Co., Ltd. (2432.T) Income Statement Analysis – Financial Results
- Logistec Corporation (LTKBF) Income Statement Analysis – Financial Results
- ECI Technology Holdings Limited (8013.HK) Income Statement Analysis – Financial Results
- Matrimony.com Limited (MATRIMONY.BO) Income Statement Analysis – Financial Results
Savara Inc. (SVRA)
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 257.00K | 0.00 | 0.00 | 0.00 | 400.00K | 54.00 | 1.55K | 0.00 | 0.00 | 0.00 | 488.96K | 300.00K | 500.00K | 500.00K | 0.00 | 496.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 44.26M | 167.00K | 367.00K | 35.04K | 1.01M | 526.00K | 363.00K | 0.00 | 146.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -44.26M | -167.00K | -367.00K | 221.96K | -1.01M | -526.00K | -363.00K | 400.00K | -145.95K | 1.55K | 0.00 | 0.00 | 0.00 | 488.96K | 300.00K | 500.00K | 500.00K | 0.00 | 496.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 86.37% | 0.00% | 0.00% | 0.00% | 100.00% | -270,270.37% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.26M | 27.88M | 28.99M | 35.04M | 38.78M | 37.17M | 18.51M | 8.18M | 28.26M | 19.44M | 12.90M | 8.09M | 5.76M | 3.69M | 6.51M | 17.92M | 15.93M | 12.00M | 8.68M | 2.74M | 749.00K | 282.97K | 946.42K | 1.02M |
| General & Administrative | 15.67M | 10.93M | 12.35M | 14.26M | 13.08M | 10.65M | 11.08M | 2.82M | 10.96M | 9.49M | 8.52M | 7.52M | 7.60M | 5.32M | 5.00M | 9.72M | 8.68M | 7.24M | 4.90M | 4.02M | 1.59M | 1.39M | 2.04M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -410.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.67M | 10.93M | 12.35M | 14.26M | 13.08M | 10.65M | 11.08M | 2.82M | 10.96M | 9.49M | 8.52M | 7.52M | 7.19M | 5.32M | 5.00M | 9.72M | 8.68M | 7.24M | 4.90M | 4.02M | 1.59M | 1.39M | 2.04M | 793.97K |
| Other Expenses | -44.19M | -765.00K | -708.00K | -638.00K | 311.00K | 526.00K | 363.00K | -43.00K | 4.00K | 508.00K | -1.35K | -5.05K | 37.57K | 19.82K | 79.73K | 168.04K | 197.78K | 176.69K | 115.55K | 41.31K | 8.97K | 428.11K | 7.67M | 0.00 |
| Operating Expenses | 15.75M | 38.04M | 40.63M | 48.66M | 52.17M | 48.35M | 29.96M | 11.35M | 39.37M | 29.01M | 21.46M | 15.70M | 13.40M | 9.03M | 11.59M | 27.81M | 24.81M | 19.41M | 13.70M | 6.80M | 2.34M | 2.10M | 10.66M | 3.72M |
| Cost & Expenses | 60.01M | 38.04M | 40.63M | 48.66M | 52.17M | 48.35M | 29.96M | 11.35M | 39.37M | 29.01M | 21.46M | 15.70M | 13.40M | 9.03M | 11.59M | 27.81M | 24.81M | 19.41M | 13.70M | 6.80M | 2.34M | 2.10M | 10.66M | 3.72M |
| Interest Income | 4.44M | 88.00 | 2.28K | 1.48K | 0.00 | 0.00 | 0.00 | 122.00K | 130.00K | 69.00K | 60.27K | 73.56K | 76.59K | 92.87K | 7.16K | 549.96K | 2.17M | 1.16M | 496.06K | 103.04K | 9.27K | 1.27K | 31.69K | 40.92K |
| Interest Expense | 0.00 | 88.00K | 2.28M | 1.48M | 70.00K | 11.00K | 1.16M | 468.00K | 603.00K | 0.00 | 0.00 | 0.00 | 11.01K | 1.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.39K | 1.39K | 53.70K | 12.02K | 23.50K |
| Depreciation & Amortization | 175.00K | 167.00K | 367.00K | 693.00K | 1.01M | 526.00K | 363.00K | 346.00K | 146.00K | 85.00K | 39.52K | 90.05K | 38.00K | 19.82K | 79.73K | 168.04K | 197.78K | 176.69K | 115.55K | 41.31K | 8.97K | 428.11K | 7.67M | 1.91M |
| EBITDA | -59.13M | -37.90M | -40.37M | -47.44M | -77.09M | -69.50M | -31.91M | -10.48M | -39.09M | -28.62M | -21.44M | -15.47M | -13.22M | -8.43M | -11.21M | -27.14M | -24.11M | -29.16M | -13.09M | -6.66M | -2.32M | -1.72M | 2.72M | -1.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -18,565.76% | 0.00% | 0.00% | 0.00% | -2,650.50% | -72,642,592.59% | -1,850,904.39% | 0.00% | 0.00% | 0.00% | -1,741.95% | -3,719.81% | -5,318.37% | -4,822.65% | 0.00% | -303.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -60.01M | -38.84M | -41.48M | -49.30M | -79.03M | -70.05M | -29.96M | -10.95M | -39.37M | -29.28M | -21.54M | -15.63M | -13.40M | -8.54M | -11.29M | -27.31M | -24.31M | -29.84M | -13.20M | -6.80M | -2.34M | -2.10M | -10.66M | -3.72M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -19,182.88% | 0.00% | 0.00% | 0.00% | -2,737.00% | -72,912,962.96% | -1,891,408.27% | 0.00% | 0.00% | 0.00% | -1,746.51% | -3,761.90% | -5,461.97% | -4,862.21% | 0.00% | -2,661.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.31M | 689.00K | -1.54M | -315.00K | 852.00K | 18.00K | -3.48M | -332.00K | -469.00K | 577.00K | 58.92K | 68.51K | -273.93K | 88.78K | -39.37K | 662.34K | 2.17M | 504.69K | -11.58M | 103.04K | 11.49K | 45.79K | -5.70M | 0.00 |
| Income Before Tax | -54.70M | -38.15M | -43.01M | -49.62M | -78.17M | -70.03M | -33.43M | -11.28M | -39.84M | -28.70M | -21.48M | -15.56M | -13.26M | -8.45M | -11.33M | -26.65M | -22.14M | 29.33M | -24.78M | -2.33M | -2.33M | -2.05M | -16.36M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -19,305.45% | 0.00% | 0.00% | 0.00% | -2,820.00% | -73,781,481.48% | -1,854,134.37% | 0.00% | 0.00% | 0.00% | -1,728.35% | -3,775.02% | -5,329.50% | -4,428.41% | 0.00% | -4,995.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 796.00K | 2.28M | 1.48M | 26.85M | -8.51M | -3.63M | -357.00K | 473.00K | -306.00K | -1.35K | -5.05K | -65.62K | -88.78K | 39.37K | 0.00 | 0.00 | 9.92M | 11.58M | 4.37M | -11.49K | 6.63K | 5.68M | -17.43K |
| Net Income | -54.70M | -38.95M | -45.30M | -51.10M | -105.03M | -61.52M | -29.80M | -10.92M | -39.84M | -28.70M | -21.48M | -15.56M | -13.26M | -8.45M | -11.33M | -26.65M | -22.14M | -29.33M | -24.78M | -6.70M | -2.33M | -2.11M | -16.34M | -3.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -19,882.10% | 0.00% | 0.00% | 0.00% | -2,730.75% | -73,781,481.48% | -1,854,134.37% | 0.00% | 0.00% | 0.00% | -1,728.35% | -3,775.02% | -5,329.50% | -4,428.41% | 0.00% | -4,995.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.33 | -0.25 | -0.34 | -0.86 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 | -19.63 | -22.86 | -32.94 | -44.88 | -169.85 | -516.69 | -430.96 | -693.77 | -724.89 | -231.21 | -120.54 | -235.41 | -1.96K | -769.94 |
| EPS Diluted | -0.33 | -0.25 | -0.34 | -0.86 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 | -19.63 | -22.86 | -32.94 | -44.88 | -169.85 | -516.69 | -430.96 | -693.77 | -724.89 | -231.21 | -120.54 | -235.41 | -1.96K | -769.94 |
| Weighted Avg Shares Out | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 3.35M | 2.32M | 1.75M | 1.09M | 680.60K | 402.51K | 188.30K | 66.68K | 51.57K | 51.38K | 42.28K | 34.19K | 28.98K | 19.35K | 8.95K | 8.34K | 4.81K |
| Weighted Avg Shares Out (Dil) | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 3.35M | 2.32M | 1.75M | 1.09M | 680.60K | 402.51K | 188.30K | 66.68K | 51.57K | 51.38K | 42.28K | 34.19K | 28.98K | 19.35K | 8.95K | 8.34K | 4.81K |
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On December 11, 2023, the Compensation Committee of Savara's Board of Directors granted...
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023...
Savara to Present at the Jefferies London Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023 at 12:00pm...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On October 3, 2023, the Compensation Committee of Savara's Board of Directors granted...
3 Penny Stocks to Provide 1,000% Returns Over the Next Decade
While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models, high debt, dwindling market share, and uncertain prospects.
The 3 Best Penny Stocks to Buy Now: September 2023
A new month arrives and with it comes new investment opportunities. We will not always need such a large capital to make our investments, for these penny stocks present us with good opportunities that we can take advantage of, with...
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On August 3, 2023, the Compensation Committee of Savara's Board of Directors granted...
Savara: A Speculative Play
Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies and has a pivotal readout...
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share and, in...
Source: https://incomestatements.info
Category: Stock Reports